Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System

Occurrence of acute cholinergic syndrome in an infant due to donepezil ingestion

“…In a retrospective study, Thornton et al 16 report the management of 189 children who became symptomatic after ingesting AChE inhibitor medications, of whom 100 were managed at home and of the remaining 89 children treated in hospital, only one 1‐year‐old boy with drooling was treated with atropine 0.25 mg IV. Garlich et al 17 report that a 14‐month‐old boy developed drowsiness and drooling after taking a 10 mg pill of donepezil and had two episodes of non‐bilious, non‐bloody emesis, and diarrhea during hospitalization, managed without the need for atropine.…”

Pharmacotherapy of Traumatic Childhood Aphasia: Beneficial Effects of Donepezil Alone and Combined With Intensive Naming Therapy

“…DP has been used in several developmental and acquired cognitive and behavioral disorders involving children and adolescents ( Biederman and Spencer, 2000 ; Popper, 2000 ; Wilens et al, 2000 ; Hardan and Handen, 2002 ; Spencer and Biederman, 2002 ; Heller et al, 2004 ; Pityaratstian, 2005 ; Doyle et al, 2006 ; Hazell, 2007 ; Spiridigliozzi et al, 2007 ; Cubo et al, 2008 ; Kishnani et al, 2010 ; Buckley et al, 2011 ; Handen et al, 2011 ; Srivastava et al, 2011 ; Castellino et al, 2012 ; Sahu et al, 2013 ; Castellino et al, 2014 ; Lassaletta et al, 2015 ; Tamasaki et al, 2016 ; Thornton et al, 2016 ). Treatment with DP in this population has proven to be safe ( Biederman and Spencer, 2000 ; Hardan and Handen, 2002 ; Heller et al, 2004 ; Spiridigliozzi et al, 2007 ; Kishnani et al, 2010 ; Handen et al, 2011 ; Castellino et al, 2012 ; Sahu et al, 2013 ; Thornton et al, 2016 ), demonstrating good efficacy profile ( Biederman and Spencer, 2000 ; Popper, 2000 ; Wilens et al, 2000 ; Hardan and Handen, 2002 ; Spencer and Biederman, 2002 ; Heller et al, 2004 ; Pityaratstian, 2005 ; Doyle et al, 2006 ; Hazell, 2007 ; Spiridigliozzi et al, 2007 ; Cubo et al, 2008 ; Buckley et al, 2011 ; Srivastava et al, 2011 ; Castellino et al, 2012 ; Castellino et al, 2014 ; Lassaletta et al, 2015 ). Therefore, we considered that the prescription of this agent for an unapproved use was appropriate for this particular case of CA.…”

“…The protocol of this study was approved by the local Ethical Research Committee (Provincial of Malaga, Spain). DP has been used in several developmental and acquired cognitive and behavioral disorders involving children and adolescents (Biederman and Spencer, 2000;Popper, 2000;Wilens et al, 2000;Hardan and Handen, 2002;Spencer and Biederman, 2002;Heller et al, 2004;Pityaratstian, 2005;Doyle et al, 2006;Hazell, 2007;Spiridigliozzi et al, 2007;Cubo et al, 2008;Kishnani et al, 2010;Buckley et al, 2011;Handen et al, 2011;Srivastava et al, 2011;Castellino et al, 2012;Sahu et al, 2013;Castellino et al, 2014;Lassaletta et al, 2015;Tamasaki et al, 2016;Thornton et al, 2016). Treatment with DP in this population has proven to be safe (Biederman and Spencer, 2000;Hardan and Handen, 2002;Heller et al, 2004;Spiridigliozzi et al, 2007;Kishnani et al, 2010;Handen et al, 2011;Castellino et al, 2012;Sahu et al, 2013;Thornton et al, 2016), demonstrating good efficacy profile (Biederman and Spencer, 2000;Popper, 2000;Wilens et al, 2000;Hardan and Handen, 2002;Spencer and Biederman, 2002;Heller et al, 2004;...…”

“…Accumulating evidence suggests that anticholinesterasic agents improve executive functions (Castellino et al, 2012;Castellino et al, 2014), sustained attention (Spiridigliozzi et al, 2007), learning, memory (Spiridigliozzi et al, 2007;Castellino et al, 2012), and language functions (Heller et al, 2004) in children. Importantly, the safety of these drugs in the pediatric population has been widely demonstrated (Biederman and Spencer, 2000;Hardan and Handen, 2002;Heller et al, 2004;Spiridigliozzi et al, 2007;Kishnani et al, 2010;Handen et al, 2011;Castellino et al, 2012;Sahu et al, 2013;Thornton et al, 2016). Over the last twenty years, the anticholinesterasic compound DP has been variously used to counteract impaired cognitive functions resulting from oncologic treatment of pediatric brain tumors (Castellino et al, 2012;Castellino et al, 2014;Lassaletta et al, 2015); to improve the core symptoms of attention-deficit/hyperactivity disorder (Biederman and Spencer, 2000;Popper, 2000;Wilens et al, 2000;Banaschewski et al, 2004;Pityaratstian, 2005) and of inattention-hyperactivity and communication abnormalities in autism spectrum disorders (Doyle et al, 2006;Hazell, 2007;Tamasaki et al, 2016).…”

Carbon science perspective in 2020: Current research and future challenges

“…The attractiveness of using AC as a universal antidote is due to its large adsorption capacity towards most organic substances, which are usually a cause of self-inflicted deliberate or inadvertent intoxication (medical drugs). In recent years, several reports, to mention but a few, on the successful use of AC as an oral adsorbent in the treatment of large numbers of patients exposed to buprenorphrine (used to treat narcotic dependence) [153], antidementia drugs [154], diarrhoea management [155], mushroom poisoning [156] and paraquat (herbicide) poisoning [157] have been published. In the latter case the authors stressed that the administration of AC within the first hour of paraquat ingestion was essential since there is no specific treatment for paraquat poisoning.…”